Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
As many of you are aware there are serial rampers on this board.
They will boggle you with science and claim that because the science is good, this company must surely succeed.
As a new investor, please do your due diligence on this company.
Look what happens on this forum when people point out the disastrous team at the company. The same usual rampers try their hardest to discredit anyone who goes against the staff at this company.
Let me spell it out for any new investor tempted to get in here.
We have Jordan Belfort style rampers on this forum who are continuously bigging up the prospect of this company in the full knowledge that it is going nowhere.
They are day trading the stock in order to make profits at YOUR EXPENSE. They know it’s a penny stock and a total gamble at best because in twenty years this company has failed to get its product to market.
This post is designed to warn potential new investors that might be lured in by the Jordan Belfort style rampers on this forum to think twice. The drug might work, but there is a reason for the failed trials (multiple failed trials), the CEO is total garbage and the communication of this company horrendous. They do not look after their shareholders at all.
Please do not make the same mistake that many of us did and get suckered in by the Jordan Belfort rampers. If they actually worked in finance, those on this forum would now be doing time for their ramping.
Do your due diligence and good luck.
A polite warning to all potential new investors.
You might be reading posts from people on here ramping this company up.
They will show you the science and claim that because the science adds up, surely this company is a good investment?
Please remember that the science has not changed in 20 years, yet the company and CEO have been unable to bring this drug to market in those 20 years.
You don’t invest in science, you invest in companies and a company that has a drug that works, but is incapable of getting it to market = a very poorly performing company.
Synairgen is a speculative gamble at best.
All new investors please BEWARE of the Jordan Belfort style rampers that want to sell you penny stock trash.
It’s very easy to look at medical studies, news or data and get excited about a drug.
But this does NOT make it a good investment.
If you notice, every ramper on here (Jordan Belfort style ramping up penny stocks to lure in new investors) will talk about the science.
When you invest in Synairgen, you are investing in the people that run the company and trusting them to be able to bring their drug to market.
None of the Belfort style rampers talk about how wonderful Marsden, the CEO is.
Or the fantastic speed things have progressed at.
The great communication of the Synairgen team with their shareholders.
The excellent trial planning done by the Synairgen team.
Lastly, the superbly written RNS skill to bolster the SP and help their loyal investors.
Of course the Jordan Belfort style rampers can not talk about these important things because they have been a total disaster, so they’ll carry on trying to lure you in by talking about the abstract science which has been the same for decades and in those decades Marsden the CEO has been completely incapable of taking this drug to market.
Having a drug that works is 10% of the picture.
Having a team that can bring that drug to market is what makes a company a success. The Synairgen team has 20 years proof of being unable to bring this drug to market.
A solid investment, or a wild speculative gamble in a poorly organised team of amateurs? Your money, your choice. But BEWARE the Belfort style rampers.
For anyone new who might think about investing in this company based on what you read, please read this.
1. Only invest what you can afford to lose.
2. The opinions that you see on here are only opinions.
Many people get carried away with the science. They believe that because the science works, that the drug this company makes is guaranteed to succeed and to become commercial. This is not true. The commercial success of a company is also down to the people working for the company and their ability (or inability, in this case).
3. So far, most the holders in this company are down 75% or more. The current CEO has had 17 years at this company and has failed to bring the drug to market within those 17 years.
4. This company has made the most monumental schoolboy blunder in their recent clinical trial, regardless of whatever other science shows that their drug works, it has failed to meet endpoints.
Please do your due diligence in to this company if you are tempted to invest. Do not get suckered in by Wolf of Wall Street style rampers on here because it’s most likely they are day trading the stock and are aware that the short term prospects of this company are very low.
Do your DD and don’t get conned by disgusting and dishonest rampers trying to flog a turkey.
Brand, how’s this for substance:
Marsden 17 years as CEO, failed to get product to market.
SP 90% down.
Polygon 80% underwater.
Yet you’re still ramping. It’s basically criminal, trying to lure in new investors. Are you trying to be the wolf of Wall Street? Conning newbies in to investing in penny stock garbage, knowing full well it’s garbage.
Brand, or they are doing EXACTLY what I am doing.
STOP ramping this stock up. You are 90% down, as are most investors here. It is disgusting to continue ramping this up, trying to deviously trick new investors in to investing in this failed company.
I already said Polygon are loading up to lower their average. They can have the same approach that I have, I work in the frigging city and have done for the last 15 years. They will lower their average and then hope for a heavily reduced buyout to recapture their initial investment.
What you and others are continuously doing is disgusting. People need to know that ramping this stock up to draw in new investors, only for a new crash to happen again (either fund raise or terrible secondary endpoint results) = shameful.
Kevin, we agree on Marsden completely.
In what world could anyone believe that a CEO is worthy to remain in that position after they have failed in 17 years to bring a drug to market?
The failure of the SPRINTER trial in such ridiculous spectacular fashion must be totally unbelievable to the likes of Pfizer or Astra etc. Marsden and whoever designed the trial (without checking up on it for a whole year that it was on) must be the biggest laughing stock in the pharmaceutical industry right now for such a ridiculous schoolboy error.
How Marsden can remain as CEO after such a terrible performance baffles me.
I only ever invested what I could afford to lose (that’s always the golden rule), however I did think (based on the science) that this would work (we all did, including Polygon), we all underestimated the lunacy of the company. I am lucky to have a job in the city and can earn the loss back within two years (very fortunately) so this is money I’ve basically forgotten about, but others are in a position where they can not. I’m not prepared to sit and occasionally look at this board to see the same people ramping the stock up when it could dangerously attract new investors when this far Synairgen and the CEO have been a failure in 17 years.
It is not fair on new investors.
If it is genuinely people who are excited by the drug and the science, therefore getting carried away with rampy posts, then they need to also be grounded by the harsh reality that right now this company is a laughing stock in the pharma world.
If Marsden does end up being forced out, I don’t see how he can go back in to pharma or biotech ever again. His record is abysmal with this company.
Alpha, I already sold my shares at 33p. I bought them back at 18p.
Gonna leave them be now. Then plug in 5k if the SP tanks again with rubbish secondary endpoint results and then just leave it.
If I can get 150k shares I’m happy to just leave it for the next decade and see if Synairgen gets bought out circa £1 a share, then at least I’m in good profit.
I think £1 a share buyout in the next decade is possible, even with this terrible bunch of amateurs leading the company, so I’m happy to wait.
As I wrote, I’m fortunate enough to have my house and car all paid off, have a family. This was money I could afford to lose, albeit a bitter pill to taste. But others are not as fortunate and others also may have invested a lot more than they could afford.
Bluntly, I think it’s disgusting to keep on ramping this stock when so far the results have been terrible and the CEO has failed in 17 years to take this drug to market.
That’s the reality.
You can uplike each other’s ramping posts as much as you want, but it’s disgusting if you are luring in new investors with these trash ramping posts when this company has been a total failure.
Kevin, finally you’re coming round to the truth.
Polygon are just lowering their average down. They have been proven to know the same as us (we all got conned in to thinking Synairgen were putting on a really good trial and that the science would speak for itself). They made the same mess up that we did.
I’d say they are lowering their average, they know eventually a takeover will happen (at a much reduced price) because Synairgen can’t take this drug to market. It’s a drug that works, but will need to be bought by pharma first. Polygon know this. If they lower their average to around £1 per share then they will be satisfied with a buyout for £250 mil and make a small profit.
That’s what they are doing IMO.
The people that ramp this stock up are disgusting and it is extremely bad taste to try to trick new investors to part with their money in this company when they know this company is going nowhere.
We have a CEO that has accomplished nothing in 17 years. If this was a football team, he would’ve been sacked long ago. They are sitting on a drug that works yet they can’t get it to market. If they were really serious they should be planning a new trial RIGHT NOW for 6 months (that’s all it should take) with 500 people, comparing SNG001 to regular standard of care and setting simple endpoints like % chance of survival compared to SoC.
It really is disgusting what some of the rampers on here are doing (still, after all the failures of this company) to try and lure in new investors. It’s blatantly obvious they are day trading it. I have come to terms that the investment is gone, I already am fortunate to have a house with mortgage paid off and nice car, so for me this was money I could afford to lose. But others are not in such a fortunate position and new investors might not be as well. So it is sickening to see the same people on here ramping this ridiculous company up, when we all know they are a bunch of amateurs.
Marsden = 17 years as CEO, can’t get the drug (which works) out to market. Says it all really.
Tommy, I wonder why Polygon bought in at £2 a share when they could’ve bought in at 11p?
Why don’t you get this through your thick skulls.
POLYGON GOT IT WRONG, they have lost millions.
Jesus, some of you are beyond a joke. You have LOST YOUR MONEY WITH THIS COMPANY because the company didn’t know how to conduct a clinical trial.
Polygon are just getting their average down, so that when a low takeover bid finally comes, they can offload their shares at less of a loss.
It’s time many of you need to grow up, you are 90% down and still clinging on to Marsden who has failed in 17 years to bring this drug to market.
You continuously up like each other’s posts, claiming it’s because of the science or because of Polygon. Yet the science and Polygon has made absolutely f11ck all to this investment.
STOP conning new investors who come on to this forum and START looking at reality.
Reality = Polygon got it wrong.
Share price is 90% down.
Synairgen do NOT know how to conduct a clinical trial and made the biggest schoolboy error (that was unchecked in an entire year).
Marsden has had 17 years to bring this to market and has failed.
Anything you, or any other rampers write = total utter BS designed to get new investors stuck in this hype train.
It’s actually sickening what you and the other rampers do on this board.
I advise all new investors NOT to listen to the rampers, this company is terrible. The board are useless and have extremely poor communications. Do NOT get caught in this silly ramped up company.
50p?
No chance. After the secondary endpoint data is revealed, SP will tank down to 10p. Then it’s the time to stack up the shares and forget about this company, it’s a nice punt for a very long term hold, if one can buy in at the 10p level.
Size, you’d like to think that they’d apply for EUA, but this is Synairgen and Marsden we are talking about.
They’ve been content for the last twenty years just plodding along, taking their time. This company didn’t even know that steroids were being used as SoC for a whole year that their biggest ever trial was being conducted. That’s the level of professionalism we have to expect now at Synairgen.
Given what horror show they did with SPRINTER (and the time it takes them to do anything) do we really believe they’ll pull a rabbit out of the hat with this?
I’d say we are better off ditching Marsden for his utter failure, starting from scratch again and getting proper endpoints to a new Phase 3 trial which simply shows % chance of saving lives and have Remdesivir and steroids as our ‘placebo’ wing.
Take 500 participants, 250 in each wing. Then if we get SNG001 to have a 40% extra chance of saving lives than Remdesivir and steroids = great success.
Any decent pharma company could probably run that trial in five countries, costing £10 mil and gets results in 6 months time.
That would be our best bet.
After those 6 months, we can apply for EUA again.
This is what the company should be setting up right now, alongside them deep dive data from the old P3.
It’s better to wait until the secondary endpoint data comes out. The SP will tank again and then we can buy in at rock bottom to lower our averages.
Wait for the results of the secondary endpoint long covid data to be revealed.
Given the massive f11ck up with the primary endpoints (company didn’t know that steroids were being used as Standard of care placebo wing in their 20 million pound, year long trial, pitiful). The results of the secondary endpoints are no doubt going to be a horror show as well.
When this happens, the price will crash down to 10/11p again.
At that stage, it’s worth popping in £5k and holding.
If we can get Marsden out soon ( he’s failed in 17 years to take this to market) and we get an ambitious CEO that wants to take SNG001 to market and explores all avenues with joint ventures and collusion with big pharma, that £5k (50k shares) could be worth £250k.
It’s worth the long term punt.
Wait for the terrible secondary endpoint data to come and then buy in the dip.
Do NOT waste good money at this price.
Two months ago this board was rampant with characters screaming ‘They’re trying to buy your cheap shares.’
They were convinced Polygon was on this board secretly trying to get people to sell so they could buy their cheap shares :D
Fast forward a couple of months and the same people are on here screaming ‘PLEASE POLYGON, please buy more!!’
The same people are ecstatic when they see a TR1 that Polygon have bought more shares and using this as a reason to ramp yet again.
For new investors, please be aware that you might get drawn in to investing in here based on the science. But that is NOT a good reason to invest in this company.
Remember, you don’t invest in the science, you invest in the people who run the company.
Always remember this when pondering this stock. The science is rock solid, but monkeys in possession of a cure are still a bunch of monkeys afterall. Synairgen is a research company, it will never become a pharma company, be aware of this should you decide to invest.
Size, you’ve basically written the same as what I’ve been saying for the last three weeks.
Except you forgot one more point:
Synairgen need to do another fund raise for cash. The Share pool is diluted further and SP goes down to 10p again.
At that point, it’s worth buying £5k’s worth (50k shares) and just holding them for the next five to ten years and see where it’s ends up.
One thing is very likely though. Synairgen themselves will not be able to take this drug further. At every opportunity they have proven far too slow, very poor foresight and unable to understand the market or any marketing opportunities. A buy out is in our best favour, take this drug out of such incompetent hands and put it in the hands of a pharma company that can bring it to market.
Synairgen have made it clear from the RNS today that they have no intention of applying for EUA based on SPRINTER or ACTIV2 data.
So what relevance is this?
Simple, it shows that the drug works.
But we know that anyway.
Unfortunately it gets us no further towards approval or a product on the market.
It’s a ten year hold IMHO.
What’s positive about that RNS?
This is just laughable.
ACTIV2 been halted AND Synairgen have no intention to apply for EUA based on SPRINTER or ACTIV2 P2 data.
All of this means a wait for many years to come.
Absolutely nothing positive at all.
They should do the next fund raise at 15p per share IMO, it might fall to 10p again, then it’s worth a decent punt.
Oh well, we’ve gone from being the biggest prospect on the stock market a month ago to the biggest loser in the last year.
Now seeing as ACTIV2 design needs to be changed which could take at least a couple of years to see us on a new trial and the trial completed, what do we reckon re a fund raise?
Surely the company are going to need to dilute the shares further, in which case the SP will fall again?
We know the product works, but now we are pretty much starting from scratch on trial designs. It’s going absolutely nowhere in the next couple of years.
So my advice remains the same as it was a few weeks ago. Buy this share if you are prepared to wait 3-10 years. One can buy in now at these prices and then also buy in when the fund raise happens (probably get to buy in around 10p at the next share dilution).
In the meantime if you want to day trade this will be a great share to get in and out of. But remember, you can still get burnt from day trading because there doesn’t look like any good news on the horizon for a long time.
Re the deep dive data and ACTIV2 P2 data, the company clearly have NO INTENTION to apply for EUA after analysing both sets of data or they would have said so in this RNS.
We have seen other covid drugs approved based on Phase 2 data, so if Synairgen had any intention to apply for EUA they would have said so, like every other company does.
Is it finally time for certain people to stop looking with their rose tinted glasses? Nah, of course not. They’ll carry on ramping this company every day with multiple posts :D :D
Accept it now, it’s finished for the foreseeable.
Size, hopefully Polygon will be able to flex and force the company to apply for EUA. That would be very good news for all shareholders.
We know the drug itself works, that’s the main point.
So it’s a long term hold for me now.
Maybe one day it will be a very pleasant surprise. But that’s all I’m thinking of it right now.